血清抗着丝粒蛋白F抗体与类风湿关节炎患者英夫利西单抗临床应答相关的前瞻性研究
本研究在三个独立队列共185例以TNFi作为一线生物制剂治疗的RA患者中,分析基线血清自身抗体与24周临床应答的关系。结果显示基线抗CENPF抗体IgG水平在英夫利西单抗应答者中显著升高,加入年龄、性别、DAS28-ESR后判别应答者的AUC为0.756,meta分析SMD为-0.65,提示抗CENPF抗体可能预测IFX应答。
要点
- 基线抗CENPF抗体水平在IFX应答者中显著高于非应答者(p<0.05)。
- 抗CENPF抗体联合年龄、性别、DAS28-ESR判别应答的AUC为0.756。
- meta分析显示抗CENPF水平与后续IFX应答显著相关,SMD为-0.65。
核心结论
- 血清抗CENPF抗体有望在启动英夫利西单抗治疗前预测RA患者的临床应答。
研究设计与样本
- 前瞻性研究,纳入三个独立队列共185例以TNFi作为一线生物制剂治疗的RA患者。
- 采用多重微珠阵列在发现队列(N=50)、验证队列(N=61)和确认队列(N=74)中检测基线自身抗体。
- 分析基线自身抗体与24周随访后临床应答的关联,并进行非参数检验、meta分析和ROC分析。
主要发现
- 基线抗CENPF抗体IgG水平在英夫利西单抗应答者(N=111)中较非应答者(N=44)显著升高(p<0.05)。
- 抗CENPF抗体加入年龄、性别、DAS28-ESR变量后判别应答者的AUC为0.756(95%CI [0.639-0.874],p=0.001)。
- 新型自身抗体与TNFi临床应答相关,且在不同TNFi间反应性谱不同。
临床怎么用
- 基线检测抗CENPF抗体可能辅助筛选更可能从英夫利西单抗获益的RA患者,指导生物制剂选择。
局限性
- 研究聚焦TNFi中英夫利西单抗的应答预测,抗CENPF抗体在其他TNFi中的预测价值需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One-third of rheumatoid arthritis (RA) patients demonstrate no clinical improvement after receiving tumor necrosis factor inhibitors (TNFi). The presence of serum autoantibodies is a hallmark in RA and may provide information on future response to treatment. The aim of this prospective study was to search for novel serum autoantibodies useful to predict clinical response to TNFi. METHODS: The autoantibody repertoire was profiled on RA patients treated with TNFi as a first line of biologic therapy (N = 185), who were recruited in three independent cohorts. The presence and levels of autoantibodies in serum at baseline were analysed in association with the clinical response after 24 weeks follow-up. A multiplex bead array built using antigens selected from an initial untargeted screening was employed to identify the autoantibodies on a discovery cohort (N = 50) and to verify and validate the results on verification (N = 61) and validation (N = 74) cohorts. Non-parametric tests, meta-analysis and Receiver Operating Curves (ROC) were performed in order to assess the clinical relevance of the observed findings. RESULTS: Novel autoantibodies were associated with the clinical response to TNFi, showing different reactivity profiles among the different TNFi. The baseline levels of IgG antibodies against Centromere protein F (CENPF), a protein related to cell proliferation, were significantly (p<0.05) increased in responders (N = 111) to infliximab (IFX) compared to non-responders (N = 44). The addition of anti-CENPF antibodies to demographic and clinical variables (age, sex, DAS28-ESR) resulted in the best model to discriminate responders, showing an area under the curve (AUC) of 0.756 (95% CI [0.639-0.874], p = 0.001). A further meta-analysis demonstrated the significant association of anti-CENPF levels with the patient's subsequent response to IFX, showing a standardized mean difference (SMD) of -0.65 (95% CI [-1.02;-0. 27], p = 0.018). CONCLUSIONS: Our study reveals for the first time the potential of circulating anti-CENPF antibodies to predict the clinical response to IFX before starting the treatment. This finding could be potentially useful to guide therapeutic decisions and may lead to further studies focusing on the role of CENPF on RA pathology.
引用
- Lourido L, Ruiz-Romero C, Picchi F, et al. Association of serum anti-centromere protein F antibodies with clinical response to infliximab in patients with rheumatoid arthritis: A prospective study. Semin Arthritis Rheum. 2020. PMID: 32920323. doi:10.1016/j.semarthrit.2020.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。